Research Topics
| D A MorrowSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 31:1460-5. 1998....- Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trialDavid A Morrow
Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 40:71-7. 2002.... - A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudyD A Morrow
TIMI Trials Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Lancet 358:1571-5. 2001..Available models for predicting mortality in STEMI include up to 45 variables, but have consistently shown advanced age, increased heart rate, and decreased blood pressure to be among the strongest predictors... - Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3D A Morrow
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 286:1356-9. 2001..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population... - Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudyD A Morrow
Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 36:1812-7. 2000.... - TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudyD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 102:2031-7. 2000..Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice... - Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B SubstudyD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Clin Chem 46:453-60. 2000..Until adequate cTnI standardization is possible, an evidence-based approach evaluating each assay at specific thresholds appears warranted... - Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 35:358-62. 2000.... - Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogramJ A de Lemos
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 140:373-8. 2000..We evaluated the combination of a baseline myoglobin assay and early (60- to 90-minute) ST resolution for risk stratification after ST-segment elevation myocardial infarction... - Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapyJ A de Lemos
Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Clin Chim Acta 298:85-97. 2000..Despite a favorable kinetic profile, however, H-FABP does not appear to represent a significant advance over myoglobin in the noninvasive detection of reperfusion after thrombolysis... - The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromesJ A de Lemos
Thrombolysis in Myocardial Infarction Study Group, Boston, USA
N Engl J Med 345:1014-21. 2001.... - Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trialD A Morrow
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 286:2405-12. 2001.... - An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUSD A Morrow
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
Eur Heart J 23:223-9. 2002..73, P=0.027). CONCLUSION: The TIMI Risk Score is a simple clinical tool for risk assessment that may aid in the early identification of patients who should be considered for treatment with potent antiplatelet therapy... - Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implicationsD A Morrow
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Cardiovasc Toxicol 1:105-10. 2001.... - Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials)Shaheeda Ahmed
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and the Department of Medicine, Harvard Medical School, USA
J Thromb Thrombolysis 21:119-29. 2006..37, 2.83, and 2.92 respectively, p < 0.001 for all). These robust estimates can be used as benchmarks to monitor the efficacy and safety of therapies in ongoing and newly completed clinical trials... - Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndromeKausik K Ray
Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
Circulation 115:3071-8. 2007..Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease... - Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarctionJessica L Mega
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
Circulation 115:2822-8. 2007..The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest... - Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
Am J Cardiol 99:344-8. 2007..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication... - Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22)Kausik K Ray
Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 98:861-5. 2006..In conclusion, in this large study of patients with ACS, we provide evidence that increased endothelial activation after ACS is independently associated with increased long-term risk of death, myocardial infarction, or recurrent ACS... - Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PRC Michael Gibson
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
Am Heart J 152:756-61. 2006..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)... - Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromesJames A de Lemos
Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
Circulation 114:550-7. 2006.... - The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 StudyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 48:37-42. 2006..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis... - Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapyJessica L Mega
TIMI Thrombolysis in Myocardial Infarction Study Group, Boston, Massachusetts 12114, USA
J Thromb Thrombolysis 22:71-6. 2006..While statins have been shown to reduce cerebrovascular events (CVE), the relationship between cholesterol, C-reactive protein (CRP), and CVE in patients treated with different statin strategies is still being explored... - A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trialC Michael Gibson
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
J Am Coll Cardiol 47:2364-73. 2006.... - Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 47:2326-31. 2006..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients... - Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionElliott M Antman
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 354:1477-88. 2006..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose... - Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trialSatish Bhadriraju
McLaren Regional Medical Center/Michigan State University, Flint, Michigan, USA
Am J Cardiol 97:1573-7. 2006..Glucose levels during ACS may be an important addition to the risk stratification of patients with ACS and a potentially important target for therapy... - Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndromeC Michael Gibson
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 97:1473-7. 2006..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome... - Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trialC Michael Gibson
Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
J Am Coll Cardiol 49:2238-46. 2007.... - Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrelMarc S Sabatine
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 49:2256-63. 2007.... 
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromesJessica L Mega
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 51:2422-9. 2008..We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an acute coronary syndrome (ACS)...- Antithrombotic therapy to support primary PCIDavid A Morrow
N Engl J Med 358:2280-2. 2008 - Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarctionMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 117:1936-44. 2008.... 
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow
TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Eur Heart J 29:1096-102. 2008....- Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromesRobert W Yeh
Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Am J Cardiol 100:1734-8. 2007..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH... - Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trialDavid A Morrow
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 155:49-55. 2008..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome... - Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACDavid A Morrow
Department of Medicine, Harvard Medical School, Boston, MA, USA
Am Heart J 154:1078-84, 1084.e1. 2007..Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding... - TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarctionChristian T Ruff
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
Am J Med 120:993-8. 2007.... - Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
Clin Chem 53:1800-7. 2007..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS... - A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
Eur Heart J 28:2070-6. 2007..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis... - Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysisSabina A Murphy
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
Eur Heart J 28:2077-86. 2007.... - Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trialBenjamin A Steinberg
Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
Am Heart J 154:54-61. 2007..We hypothesized that adjustment for baseline risk would minimize such variations... - Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysisRoberto R Giraldez
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
Eur Heart J 28:1566-73. 2007..We compared outcomes of ST-elevation myocardial infarction (STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin (UFH) to support fibrinolysis... - Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)Emmanouil S Brilakis
Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Am J Cardiol 102:552-8. 2008..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy... - Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)David A Morrow
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Circulation 113:1745-52. 2006..At 30 days, Lp-PLA2 activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels... - Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studiesJames L Januzzi
Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
Am Heart J 151:360-6. 2006..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker... - Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-ThromboStephen D Wiviott
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
Circulation 109:580-6. 2004..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)... - Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and thMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 109:874-80. 2004..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI... - C-reactive protein, inflammation, and coronary riskPaul M Ridker
Center for Cardiovascular Disease in Women, Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Cardiol Clin 21:315-25. 2003..Ongoing and future investigation will clarify the specific pathophysiologic relationships through which these markers correlate with adverse prognosis... - Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortalityC Michael Gibson
TIMI Study Chairman s Office, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
J Am Coll Cardiol 42:1535-43. 2003..We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis... - Soluble CD40L: risk prediction after acute coronary syndromesNerea Varo
Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA
Circulation 108:1049-52. 2003..Notably, combined assessment of sCD40L with cTnI complements prognostic information for death and MI... - Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategyDavid A Morrow
Circulation 108:250-2. 2003 - Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18David A Morrow
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 41:1264-72. 2003.... - Assessing the success of fibrinolysis: can we let the interventionalist rest?David A Morrow
Am Heart J 145:380-2. 2003 - Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or ConservatiMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
J Am Coll Cardiol 40:1761-8. 2002.... - Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administrationHoward A Cooper
Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
Am Heart J 144:790-5. 2002..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming... - The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studiesJames A de Lemos
Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
J Am Coll Cardiol 40:238-44. 2002..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)... - Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionGraham C Wong
Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
Circulation 106:202-7. 2002..Independent of the presence of thrombus and abnormal flow in the epicardial artery, impaired tissue level perfusion is associated with a 1.8-fold increased risk of cTnT elevation... - Identification of patients at high risk for death and cardiac ischemic events after hospital dischargeMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
Am Heart J 143:966-70. 2002..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital... - Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarctionC Michael Gibson
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 43:1170-6. 2004.... - Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarctionMasahisa Shimpo
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
Circulation 109:2186-90. 2004..These data suggest that ST2 may be a useful biomarker and that this novel inflammatory receptor may play a role in cardiac pathophysiology... - Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Circulation 112:3846-54. 2005..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study... - Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray
Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
J Am Coll Cardiol 46:1417-24. 2005.... - Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudyStephen D Wiviott
Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
J Am Coll Cardiol 46:1411-6. 2005..This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy... - Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and SymptomsJessica L Mega
TIMI Study Group, Brigham and Women's Hospital, Boston, Mass 02115, USA
Am Heart J 149:846-50. 2005..These findings likely explain in part the particular benefit of potent antithrombin and antiplatelet agents among patients with higher risk scores... - Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
J Am Coll Cardiol 45:1644-8. 2005..The aim of this research was to compare relative efficacy of different statin regimens in achieving the dual goals of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) reduction... - Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-ThroElliott M Antman
TIMI Study Group, Boston, MA 02115, USA
Am Heart J 149:217-26. 2005 - Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudyKausik K Ray
TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA, USA
Eur Heart J 26:440-6. 2005.... - Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarctionDimitrios Karmpaliotis
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Am J Cardiol 94:1113-7. 2004..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders... - Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarctionSaihari Sadanandan
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
J Am Coll Cardiol 44:564-8. 2004..We hypothesized that elevated B-type natriuretic peptide (BNP) levels would be associated with a greater severity of angiographic disease and a greater extent of myocardium at risk... - B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudyJessica L Mega
TIMI Study Group, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 44:335-9. 2004..These data support the value of combining markers of hemodynamic stress with traditional approaches to risk assessment in acute myocardial infarction... - Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromesStephen D Wiviott
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Clin Chim Acta 346:119-28. 2004..Future research is needed to identify therapies of particular benefit for patients with ACS and natriuretic peptide elevation... - Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18John V Wylie
Division of Cardiology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Mass 02215, USA
Am Heart J 148:173-80. 2004..We developed and validated a risk score to predict which patients will develop CHF... - Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusionRobert P Giugliano
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
Am J Cardiol 93:1362-7, A5-6. 2004..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography... - Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
Circulation 105:1760-3. 2002..Little is known, however, about the utility of these biomarkers in combination...